<DOC>
	<DOCNO>NCT02573636</DOCNO>
	<brief_summary>The objective study evaluate predictive value TMPRSS2-ERG gene fusion PTEN patient high risk prostate cancer treat first line LHRH agonist biochemical failure .</brief_summary>
	<brief_title>The Predictive Value Coexisting TMPRSS2-ERG Gene Fusion PTEN Deletion Prostate Cancer Patients With Biochemical Failure Status Post Salvage Radical Radiation Therapy</brief_title>
	<detailed_description>The objective study evaluate predictive value TMPRSS2-ERG gene fusion PTEN patient high risk prostate cancer treat first line LHRH agonist biochemical failure . Patients study treated standard hormonal treatment . Patients remain treatment regardless rise PSA . PSA , systemic therapy maybe add patient oligometastasis could treat radiation therapy ; would discretion treat oncologist . The primary endpoint study determine predictive value TMPRSS2-ERG gene fusion PTEN hormonal refractory free survival clinical progression rate three year . The secondary endpoint evaluate relation Gleason score TMPRSS2-ERG gene fusion PTEN independently together , relation T stage TMPRSS2-ERG gene fusion PTEN independently together , determine association marker overall survival .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>T3a + PSA &gt; 20 Gleason 8 high Karnofsky performance status â‰¥ 70 . Signed studyspecific inform consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>